Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.

Ruzzolini J, Laurenzana A, Andreucci E, Peppicelli S, Bianchini F, Carta F, Supuran CT, Romanelli MN, Nediani C, Calorini L.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):391-397. doi: 10.1080/14756366.2019.1706090.

PMID:
31865754
2.

Oleuropein, a Bioactive Compound from Olea europaea L., as a Potential Preventive and Therapeutic Agent in Non-Communicable Diseases.

Nediani C, Ruzzolini J, Romani A, Calorini L.

Antioxidants (Basel). 2019 Nov 22;8(12). pii: E578. doi: 10.3390/antiox8120578. Review.

3.

Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells.

Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1249. doi: 10.3390/cancers11091249.

4.

Anoikis Resistance as a Further Trait of Acidic-Adapted Melanoma Cells.

Peppicelli S, Ruzzolini J, Bianchini F, Andreucci E, Nediani C, Laurenzana A, Margheri F, Fibbi G, Calorini L.

J Oncol. 2019 Jun 2;2019:8340926. doi: 10.1155/2019/8340926. eCollection 2019.

5.

Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.

Bianchini F, Portioli E, Ferlenghi F, Vacondio F, Andreucci E, Biagioni A, Ruzzolini J, Peppicelli S, Lulli M, Calorini L, Battistini L, Zanardi F, Sartori A.

Cancer Lett. 2019 Apr 1;446:25-37. doi: 10.1016/j.canlet.2018.12.021. Epub 2019 Jan 11.

PMID:
30639534
6.

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.

Laurenzana A, Margheri F, Biagioni A, Chillà A, Pimpinelli N, Ruzzolini J, Peppicelli S, Andreucci E, Calorini L, Serratì S, Del Rosso M, Fibbi G.

EBioMedicine. 2019 Jan;39:194-206. doi: 10.1016/j.ebiom.2018.12.024. Epub 2019 Jan 2.

7.

Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies.

Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Scardigli A, Romani A, la Marca G, Nediani C, Calorini L.

Nutrients. 2018 Dec 8;10(12). pii: E1950. doi: 10.3390/nu10121950.

8.

SOX2 as a novel contributor of oxidative metabolism in melanoma cells.

Andreucci E, Pietrobono S, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Stecca B, Calorini L.

Cell Commun Signal. 2018 Nov 22;16(1):87. doi: 10.1186/s12964-018-0297-z.

9.

The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.

Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, Supuran CT, Calorini L.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. doi: 10.1080/14756366.2018.1532419.

10.

Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.

Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J, Bianchini F, Biagioni A, Supuran CT, Calorini L.

J Mol Med (Berl). 2017 Dec;95(12):1341-1353. doi: 10.1007/s00109-017-1590-9. Epub 2017 Sep 19.

PMID:
28929255
11.

Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.

Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Margheri F, Laurenzana A, Fibbi G, Pimpinelli N, Calorini L.

Cancer Lett. 2017 Nov 1;408:43-54. doi: 10.1016/j.canlet.2017.08.010. Epub 2017 Aug 18.

PMID:
28826720
12.

The acidic microenvironment as a possible niche of dormant tumor cells.

Peppicelli S, Andreucci E, Ruzzolini J, Laurenzana A, Margheri F, Fibbi G, Del Rosso M, Bianchini F, Calorini L.

Cell Mol Life Sci. 2017 Aug;74(15):2761-2771. doi: 10.1007/s00018-017-2496-y. Epub 2017 Mar 22. Review.

PMID:
28331999

Supplemental Content

Loading ...
Support Center